Clinical Trials in Austin

Showing 1501-1520 of 15,205 trials

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

NCT07129252

This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.

SST2-positive Neuroendocrine NeoplasmsNeuroendocrine TumorsNeuroendocrine Neoplasm

Crinetics Pharmaceuticals Inc.150 participantsStarted Nov 2025

Duarte, California, United States • Newport Beach, California, United States • Orange, California, United States +18 more locations

COMPLETEDPhase 3< 1 mile

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

NCT03142334

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have undergone nephrectomy and have intermediate-high risk, high risk, or M1 no evidence of disease (M1 NED) renal cell carcinoma (RCC) with clear cell component. The primary study hypothesis is that pembrolizumab is superior to placebo with respect to Disease-free Survival (DFS) as assessed by the Investigator in male and female participants with intermediate-high risk, high risk and M1 NED RCC.

Renal Cell Carcinoma

Merck Sharp & Dohme LLC994 participantsStarted Jun 2017

Phoenix, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +248 more locations

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

Find Trials by Condition in Austin

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

OsteoGen Plug vs. Freeze-dried Bone Allograft With Collagen Barrier

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision